http://venturebeat.com/2007/07/12/bioheart-a-risky-stem-cell-company-boosts-its-ipo-hopes/ News About Tech, Money and Innovation Wed, 25 Nov 2009 06:07:42 +0000 http://wordpress.org/?v=2.8.5 hourly 1 http://venturebeat.com/2007/07/12/bioheart-a-risky-stem-cell-company-boosts-its-ipo-hopes/comment-page-1/#comment-795845 Three yards and a cloud of dust: Bioheart makes it across the IPO goal line, but with little to show for its struggles » VentureBeat Wed, 20 Feb 2008 03:02:13 +0000 http://venturebeat.com/2007/07/12/bioheart-a-risky-stem-cell-company-boosts-its-ipo-hopes/#comment-795845 [...] a cardiac cell therapy called MyoCell, has shown decidedly mixed results in clinical trials, as I detailed back in July. Add to that its shaky cash position — just over $9 million in cash and cash equivalents as [...] [...] a cardiac cell therapy called MyoCell, has shown decidedly mixed results in clinical trials, as I detailed back in July. Add to that its shaky cash position — just over $9 million in cash and cash equivalents as [...]

]]> http://venturebeat.com/2007/07/12/bioheart-a-risky-stem-cell-company-boosts-its-ipo-hopes/comment-page-1/#comment-739412 VentureBeat » Life sciences briefing: Thursday, Jan. 17, 2007 Thu, 17 Jan 2008 21:17:35 +0000 http://venturebeat.com/2007/07/12/bioheart-a-risky-stem-cell-company-boosts-its-ipo-hopes/#comment-739412 [...] Bioheart’s woes started last October, when it abruptly slashed its offering price and fired its underwriters. The company’s IPO has lingered on life support ever since. We gave readers some good reasons to be skeptical about Bioheart — which, notably, is backed by former football great Dan Marino, among others — as long ago as last July. [...] [...] Bioheart’s woes started last October, when it abruptly slashed its offering price and fired its underwriters. The company’s IPO has lingered on life support ever since. We gave readers some good reasons to be skeptical about Bioheart — which, notably, is backed by former football great Dan Marino, among others — as long ago as last July. [...]

]]> http://venturebeat.com/2007/07/12/bioheart-a-risky-stem-cell-company-boosts-its-ipo-hopes/comment-page-1/#comment-594218 VentureBeat » Life sciences briefing: Wednesday, Oct. 24, 2007 Wed, 24 Oct 2007 19:07:17 +0000 http://venturebeat.com/2007/07/12/bioheart-a-risky-stem-cell-company-boosts-its-ipo-hopes/#comment-594218 [...] badly, with shares now down 16 percent. Next up is Bioheart, which we’ve covered here and here, and whose star-crossed IPO is still scheduled for this [...] [...] badly, with shares now down 16 percent. Next up is Bioheart, which we’ve covered here and here, and whose star-crossed IPO is still scheduled for this [...]

]]> http://venturebeat.com/2007/07/12/bioheart-a-risky-stem-cell-company-boosts-its-ipo-hopes/comment-page-1/#comment-575836 VentureBeat » I told you so: Eat your Bioheart out Fri, 12 Oct 2007 17:42:22 +0000 http://venturebeat.com/2007/07/12/bioheart-a-risky-stem-cell-company-boosts-its-ipo-hopes/#comment-575836 [...] company’s value — and fired its underwriters may not be exactly what I predicted when I hazed the company back in July– but it’ll certainly do for [...] [...] company’s value — and fired its underwriters may not be exactly what I predicted when I hazed the company back in July– but it’ll certainly do for [...]

]]>